Top-Rated Analysts

Cowen Maintains Outperform On Celgene Following ASH Meeting; Keeps $110 PT

Cowen analyst Eric Schmidt maintained an Outperform rating on Celgene Corporation (NASDAQ:CELG) with a price target of $110, which, surprisingly, represents a potential …

Wedbush Maintains Outperform On Intercept Pharmaceuticals Following PBC Supergroup Meta-Analysis Publication

In a research report issued December 7, 2014, Wedbush analyst Liana Moussatos maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT), as the company announced …

Cowen Maintains Outperform On Sunesis Pharmaceuticals Following Investor Meeting At ASH

In a research report sent to investors, Cowen analyst Eric Schmidt maintained an Outperform rating on Sunesis Pharmaceuticals (NASDAQ:SNSS). No price target was provided.

Cowen Maintains Outperform On Agios Pharmaceuticals As AG-221 Moving In On Pivotal Trials

Cowen analyst Eric Schmidt maintained an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO), as the company announced new data from its ongoing phase 1 trial …

BMO Raises Apple Price Target As December And March Quarters Could Be Peak Growth Quarters

In a research report released today, BMO analyst Keith Bachman maintained an Outperform rating on Apple (NASDAQ:AAPL) and raised his price target to $123 …

Apple’s Stock Has Healthy Upside Over The Next Year, Says Cantor

In a research report released this morning, Cantor analyst Brian White maintained a Buy rating on Apple (NASDAQ:AAPL) with a $143 price target, …

RBC Reiterates Outperform On Netflix Following Surveys Results

In a research report issued after close, RBC analyst Mark Mahaney reiterated an Outperform rating on Netflix (NASDAQ:NFLX) with a price target of …

Deutsche Bank Raises Avago Technologies Price Target As FBAR Momentum Continues

Deutsche Bank analyst Ross Seymore today joined the crowd, maintaining a Buy rating on Avago Technologies (NASDAQ:AVGO) and raising the price target to $115 (from …

After Three Challenging Years, We Believe Change Is Inevitable For IBM In 2015, Says Cantor

In a research report sent to investors today, Cantor analyst Brian White reiterated a Buy rating on International Business Machines (NYSE:IBM) with a …

We Expect GW’s Shares To Outperform As Its Pipeline Progresses, Says Cowen

Cowen analyst Phil Nadeau reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ:GWPH) with a price target of $110, as the company announced financial …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts